Vontobel Holding’s ImmunityBio IBRX Stock Holding History

Vontobel Holding’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,343	Closed	-$194K	–	1507
2026 Q1	$194K	Buy	25,343 +10,661	+73%	+$73K	﹤0.01%	1117
2025 Q4	$29.1K	Sell	14,682 -11,109	-43%	-$25.2K	﹤0.01%	1422
2025 Q3	$63.4K	Buy	25,791 +15,791	+158%	+$40.7K	﹤0.01%	1316
2025 Q2	$26.4K	Sell	10,000 -6,000	-38%	-$16.1K	﹤0.01%	1253
2025 Q1	$48.2K	Sell	16,000 -8,000	-33%	-$24.2K	﹤0.01%	1063
2024 Q4	$61.4K	Hold	24,000	–	–	﹤0.01%	1062
2024 Q3	$89.3K	Hold	24,000	–	–	﹤0.01%	1037
2024 Q2	$152K	Buy	+24,000	New	+$158K	﹤0.01%	1006

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vontobel Holding's IBRX Position: Q2 2026 in Review

Vontobel Holding sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 25,343 shares — an estimated $194K sold.

Vontobel Holding first reported a position in IBRX in Q2 2024 and held it in 8 quarters. The position peaked at $194K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Vontobel Holding reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Vontobel Holding sold 25,343 ImmunityBio shares in Q2 2026, an estimated $194K.
Vontobel Holding first reported a position in ImmunityBio in Q2 2024 and held it in 8 quarters.
Vontobel Holding's ImmunityBio position peaked at $194K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.